Stock Events

Stock Events

Processa Pharmaceuticals 

$2.53
60
-$0.2-7.17% Tuesday 19:59

Statistics

Day High
2.72
Day Low
2.45
52W High
19.63
52W Low
1.76
Volume
30,666
Avg. Volume
58,500
Mkt Cap
143.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-2
-1.41
-0.81
-0.22
Expected EPS
-1
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-23.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PCSA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on developing drugs for critical diseases, similar to Processa's focus on unmet medical needs, making them direct competitors in the pharmaceutical market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen develops innovative human therapeutics, including treatments for serious illnesses, competing with Processa Pharmaceuticals in the biopharmaceutical sector.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is involved in the discovery, development, and manufacture of healthcare products, including medicines and vaccines, competing with Processa in the pharmaceuticals market.
Merck
MRK
Mkt Cap214.76B
Merck operates in the pharmaceutical industry, focusing on drugs for conditions with significant unmet needs, directly competing with Processa Pharmaceuticals.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a research-based biopharmaceutical company with a similar focus on serious diseases, making it a competitor to Processa Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a global biopharmaceutical company focusing on discovering, developing, and delivering innovative medicines, competing with Processa in the area of serious and life-threatening diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovative drug development, particularly in areas of high unmet medical need, positioning it as a competitor to Processa.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating new possibilities in medicine to cure diseases and improve people's lives, competing with Processa in the pharmaceutical innovation sector.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on patented medicines, generics, and biosimilars, with a strong emphasis on research and development, making it a competitor to Processa Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in the pharmaceutical and biopharmaceutical market, focusing on the development of new medicines, directly competing with Processa Pharmaceuticals in the area of addressing unmet medical needs.

About

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Show more...
CEO
Mr. George K. Ng Esq., J.D.
Employees
10
Country
US
ISIN
US74275C4033

Listings

XNAS
US
PCSA
BOATS
BOATS
PCSA.BOATS

0 Comments

Share your thoughts

FAQ

What is Processa Pharmaceuticals stock price today?▼
The current price of PCSA is $2.53 USD — it has decreased by -7.17% in the past 24 hours. Watch Processa Pharmaceuticals stock price performance more closely on the chart.
What is Processa Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Processa Pharmaceuticals stocks are traded under the ticker PCSA.
Is Processa Pharmaceuticals stock price growing?▼
PCSA stock has risen by +9.78% compared to the previous week, the month change is a +16.36% rise, over the last year Processa Pharmaceuticals has showed a -75.49% decrease.
What is Processa Pharmaceuticals market cap?▼
Today Processa Pharmaceuticals has the market capitalization of 143.03M
When is the next Processa Pharmaceuticals earnings date?▼
Processa Pharmaceuticals is going to release the next earnings report on May 15, 2026.
What is Processa Pharmaceuticals revenue for the last year?▼
Processa Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Processa Pharmaceuticals net income for the last year?▼
PCSA net income for the last year is -23.7M USD.
How many employees does Processa Pharmaceuticals have?▼
As of April 01, 2026, the company has 10 employees.
In which sector is Processa Pharmaceuticals located?▼
Processa Pharmaceuticals operates in the Health Care sector.
When did Processa Pharmaceuticals complete a stock split?▼
The last stock split for Processa Pharmaceuticals was on December 17, 2025 with a ratio of 1:25.
Where is Processa Pharmaceuticals headquartered?▼
Processa Pharmaceuticals is headquartered in Hanover, US.